Clinical Trials
158 trialsNCT03520686 2026-05-26
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 3 Terminated
NCT06704724 2026-05-22
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Phase 1 Terminated
NCT04158141 2026-05-19
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
NRG Oncology
Phase 3 Terminated
NCT03645928 2026-05-15
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Iovance Biotherapeutics, Inc.
Phase 2 Terminated
NCT03337698 2026-05-12
Morpheus Lung
Hoffmann-La Roche
Phase 1/2 Terminated
NCT05815160 2026-05-04
Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
Debiopharm International SA
Phase 1 Terminated
NCT06897579 2026-04-28
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Terminated
NCT03737994 2026-04-23
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT04638582 2026-04-17
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 2 Terminated
NCT06173505 2026-03-13
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Xencor, Inc.
Phase 1/2 Terminated
NCT04832854 2026-03-11
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT05636267 2026-03-09
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
Akeso
Phase 1/2 Terminated
NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT03631199 2026-02-25
CANOPY-1
Novartis
Phase 3 Terminated
NCT03559049 2026-02-12
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT05223647 2026-01-28
TRIPLEX
Norwegian University of Science and Technology
Phase 3 Terminated
NCT05746481 2026-01-22
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
University of Pittsburgh
Phase 2 Terminated
NCT04765709 2025-12-16
BRIDGE
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
NCT06280196 2025-12-02
A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC
Bio-Thera Solutions
Phase 3 Terminated
NCT04964960 2025-10-31
Pembro+Chemo in Brain Mets
University of Kentucky
Phase 2 Terminated
NCT04524689 2025-10-29
CARMEN-LC05
Sanofi
Phase 2 Terminated
NCT05469178 2025-10-29
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
BerGenBio ASA
Phase 1/2 Terminated
NCT04619433 2025-09-23
A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Terminated
NCT03777124 2025-07-04
Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Terminated
NCT06140407 2025-06-05
Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT04870112 2025-04-17
SCope-D1
AstraZeneca
Phase 1 Terminated
NCT06094296 2025-04-16
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 2 Terminated
NCT04512430 2025-04-02
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
Fundación GECP
Phase 2 Terminated
NCT04786964 2025-04-02
CONTERNO
Checkpoint Therapeutics, Inc.
Phase 3 Terminated
NCT05267470 2025-03-25
FORTITUDE-201
Amgen
Phase 1 Terminated
NCT05911308 2025-03-21
Abequolixron (RGX-104) and Durvalumab in Lung Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1 Terminated
NCT04101357 2025-03-18
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
BioNTech SE
Phase 1/2 Terminated
NCT05543629 2025-03-18
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT05241873 2025-02-10
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Blueprint Medicines Corporation
Phase 1 Terminated
NCT04856176 2025-01-01
A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
Tufts Medical Center
Phase 2 Terminated
NCT04923776 2024-12-30
Liver Directed RT + Chemo-immunotherapy for ES-SCLC
Columbia University
Phase 2 Terminated
NCT03717415 2024-12-27
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
Phase 1/2 Terminated
NCT04364048 2024-12-20
Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04951115 2024-11-26
A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer
Weill Medical College of Cornell University
Phase 2 Terminated
NCT04325698 2024-10-01
A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC
Pfizer
Phase 3 Terminated
NCT00791154 2024-08-23
SCLC
NantCell, Inc.
Phase 1/2 Terminated
NCT05583188 2024-07-19
VIGOR
Galvanize Therapeutics, Inc.
Phase 4 Terminated
NCT02974426 2024-06-12
To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
Shanghai Chest Hospital
Phase 3 Terminated
NCT05493501 2024-05-02
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
EQRx International, Inc.
Phase 3 Terminated
NCT03866980 2024-04-03
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
Akeso
Phase 3 Terminated
NCT03699956 2024-03-26
REPLATINUM
EpicentRx, Inc.
Phase 3 Terminated
NCT04610684 2024-03-13
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04816214 2024-03-05
GEOMETRY-E
Novartis
Phase 3 Terminated
NCT03840902 2024-01-16
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
EMD Serono
Phase 2 Terminated